Replies

A clinical trial for an experimental coronavirus vaccine has begun recruiting participants in Seattle, but researchers did not first show that the vaccine triggered an immune response in animals, as is normally required.

https://www.livescience.com/coronavirus-vaccine-trial-no-animal-testing.html

Let's see. Moderna took an unconventional path to get to clinical trials over a year ago.

Since then we've had very large stage 2 and stage 3 trials in humans plus probably close to 1M doses of the vaccine given in the wild with only mild side effects.

What, exactly, is your point?

The two vaccines on early phase of the tests I looked in to

Oxford–AstraZeneca COVID-19 vaccine
standard dose there was 23 severe reactions on page 16
https://www.thelancet.com/cms/10.1016/S0140-6736(20)32466-1/attachment/f9742c1b-2e28-4d3f-aaff-9d6f0302f673/mmc1.pdf

Pfizer vaccine they played a Shell game in testing. The Pfizer vaccine that went to millions of people is BNT162b2 the standard dose they used in testing BNT162b1
They did have lots of adverse reactions with BNT162b2. Even with most of them getting low and medium doses.
https://clinicaltrials.gov/ct2/show/record/NCT04368728

Test on going unknown for long term effect. Though we have some long results with mRNA measles vaccine that uses the same enzyme with the reverse transcriptase which is the problem
They're still in the test phase of mRNA vaccines. Studies that have been made about 1/3 of the test subjects had epitope, also known as antigenic determinant or pathogenic priming (binding antibodies.) Another 1/3 they where not sure if they had epitope or not. Found here Mapping of topoisomerase II α epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1905127/